FibroGen's Earnings Outlook
Portfolio Pulse from Benzinga Insights
FibroGen (NASDAQ:FGEN) is expected to report a quarterly EPS of $-0.42 on Monday, 2024-02-26. Analysts and investors will be looking for the company to beat this estimate and provide positive guidance for the next quarter. FibroGen's past earnings performance shows a mixed record of beating and missing EPS estimates, with the stock price reacting variably. Currently, shares are trading at $1.89, down 91.21% over the last 52 weeks, indicating a negative sentiment among long-term shareholders.
February 23, 2024 | 6:01 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
FibroGen is anticipated to report a quarterly EPS of $-0.42, with investors hoping for a beat and positive future guidance. The stock has seen a significant decline over the past year, indicating potential volatility around the earnings announcement.
Given FibroGen's recent stock performance and history of mixed earnings results, the upcoming earnings report could have a neutral to slightly positive impact if the company beats estimates and provides optimistic guidance. However, the significant yearly decline suggests underlying challenges that may not be fully mitigated by a single earnings report.
CONFIDENCE 80
IMPORTANCE 90
RELEVANCE 100